6:24 PM
Dec 20, 2013
 |  BC Extra  |  Company News

CHMP backs J&J TB compound, Piramal imaging agent

EMA's CHMP recommended conditional approval of an MAA from Johnson & Johnson (NYSE:JNJ) for Sirturo bedaquiline to treat pulmonary multi-drug resistant tuberculosis (MDR-TB) in adults. The recommendation covers use of bedaquiline as part of a combination therapy when alternative treatments cannot be used due to resistance or intolerance. Late last year, FDA granted accelerated...

Read the full 258 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >